FDA achievements overlooked by critics

It's "tremendously unfair" yet in court it's an effective criticism of the FDA that it is undermanned and sometimes comes up short of fulfilling its mission. But "the amazing thing is how well FDA responds to the challenge" of being asked to do more with less money, writes Jim Beck in The Drug and Device Law blog. The agency faces globalization of food and drug regulation and is seeking harmonization with regulators around the world; it's also scrutinizing importers and moving to risk-based inspections and enforcement. Blog

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.